Peregrine Pharmaceuticals Opens Enrollment In Phase II Clinical Trial Of Bavituximab In Patients With Advanced Breast Cancer

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapies for the treatment of cancer and hepatitis C virus infection (HCV), announced that patient screening has begun in a clinical trial designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with advanced breast cancer.

More: continued here

Filed under: Breast Cancer on February 7th, 2008